Hemofil M (antihemophilic factor, human)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Antihemophilic factor (human) is a preparation of antihemophilic factor (blood coagulation factor VIII) prepared from pooled human plasma. Antihemophilic factor/von Willebrand factor complex (human) is a preparation of antihemophilic factor and von Willebrand factor prepared from pooled human plasma.
USES: This medication is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to prevent bleeding. People with low factor VIII levels are at risk for bleeding longer after an injury/surgery and for bleeding inside the body (especially into the joints and muscles).
This product contains human factor VIII, also called antihemophilic factor. This product is used to temporarily replace the missing factor VIII, a protein (clotting factor) that is normally in the blood, so that the blood can clot and the bleeding can stop.
Generic name: antihemophilic factor, human
Pronunciation: (AN-tye-HEE-moe-FIL-ik-FAK-tor)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Hemofil M
Indications
The following indications are listed for Hemofil M:
- Bleeding Episode In Hemophilia A
- Bleeding Prevention In Hereditary Factor Viii Deficiency
- Hemophilia A
Also known as: Bleeding Prevention In Classic Hemophilia, Bleeding Prevention In Congenital Factor Viii Deficiency, Bleeding Prevention In Hemophilia A, Bleeding Prophylaxis In Hemophilia A, Congenital Factor Viii Deficiency Disease, Hemorrhage Prophylaxis In Hemophilia A, Hemorrhaging In Hemophilia A, Prevention Of Bleeding Episode In Hemophilia A.
Dosing
Dosage of antihemophilic factor (human) and antihemophilic factor/von Willebrand factor complex (human) is expressed in terms of international units (IU, units); 1 unit of antihemophilic factor is approximately equivalent to the amount of factor VIII in 1 mL of fresh pooled human plasma. In general, administration of 1 unit/kg of these antihemophilic factor preparations will increase the circulating factor VIII level by approximately 2 units/dL (2%).
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.